- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 希望,健康 的帖子
9 Feb 2015
Fiscal 2015 First Quarter and Recent Company Highlights
Expanded the management team with the appointment of Susan Boynton as Vice President, Regulatory Affairs and Patrick O'Brien as General Counsel
Presented initial data from the ongoing Phase 2a study of ARC-520, our RNAi therapeutic candidate for the treatment of chronic hepatitis B infection, in the late-breaking poster session at the 2014 American Association for the Study of Liver Diseases Meeting (AASLD)
Delivered a plenary presentation at AASLD with new preclinical efficacy data on ARC-AAT, our RNAi therapeutic candidate for the treatment of liver disease associated with Alpha-1 antitrypsin deficiency
Filed an application for approval to begin a Phase 1 clinical trial of ARC-AAT
Submitted an IND application to the U.S. Food and Drug Administration to begin Phase 2b multiple dose studies
Completed dosing of 3 & 4 mg/kg cohorts in Phase 2a study of ARC-520
2015年财政年度第一季度和近期公司亮点
扩大了管理团队与苏珊博因顿被任命为副总裁,法规事务和帕特里克奥布莱恩为总法律顾问
来自ARC-520正在进行2a期研究中提出的初始数据,我们的RNAi治疗候选人的慢性乙肝感染的治疗,在2014年美国协会的最新海报会议肝病会议研究(AASLD)
发表了演讲全体会议在AASLD与ARC-AAT,我们的RNAi治疗候选人与α-1抗胰蛋白酶缺乏相关的肝脏疾病的新治疗临床疗效数据
申请批准,开始ARC-AAT的1期临床试验的申请
提交了IND申请,美国食品和药物管理局开始2b期多剂量的研究
3&4毫克/公斤的同伙在ARC-520的2a期研究已完成加药 |
|